Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 14000 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Down 50.0 %
The company has a market capitalization of C$663,150.00, a price-to-earnings ratio of -0.50 and a beta of -0.02. The business’s 50-day moving average is C$0.01 and its 200-day moving average is C$0.01. The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Read More
- Five stocks we like better than Aequus Pharmaceuticals
- Pros And Cons Of Monthly Dividend Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- How to buy stock: A step-by-step guide for beginnersÂ
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
